Rise of the preprints

Our publishing model is changing

Open Access options available from January 2021, read more

Latest Research

  • Perspective |

    Beltran and colleagues discuss the challenges in treating metastatic prostate cancer and strategies to accelerate precision oncology and improve therapy and clinical decisions in this setting.

    • Joaquin Mateo
    • , Rana McKay
    • , Wassim Abida
    • , Rahul Aggarwal
    • , Joshi Alumkal
    • , Ajjai Alva
    • , Felix Feng
    • , Xin Gao
    • , Julie Graff
    • , Maha Hussain
    • , Fatima Karzai
    • , Bruce Montgomery
    • , William Oh
    • , Vaibhav Patel
    • , Dana Rathkopf
    • , Matthew Rettig
    • , Nikolaus Schultz
    • , Matthew Smith
    • , David Solit
    • , Cora Sternberg
    • , Eliezer Van Allen
    • , David VanderWeele
    • , Jake Vinson
    • , Howard R. Soule
    • , Arul Chinnaiyan
    • , Eric Small
    • , Jonathan W. Simons
    • , William Dahut
    • , Andrea K. Miyahira
    •  & Himisha Beltran
  • Article |

    Garon and colleagues demonstrate that the association of HLA supertype B44 with response to immune checkpoint blockade in melanoma but not NSCLC is related to differential mutational features that influence HLA binding of neoepitopes.

    • Amy L. Cummings
    • , Jaklin Gukasyan
    • , Henry Y. Lu
    • , Tristan Grogan
    • , Gemalene Sunga
    • , Charlene M. Fares
    • , Nicholas Hornstein
    • , Jesse Zaretsky
    • , James Carroll
    • , Benjamin Bachrach
    • , Wisdom O. Akingbemi
    • , Debory Li
    • , Zorawar Noor
    • , Aaron Lisberg
    • , Jonathan W. Goldman
    • , David Elashoff
    • , Alex A. T. Bui
    • , Antoni Ribas
    • , Steven M. Dubinett
    • , Maura Rossetti
    •  & Edward B. Garon
  • Article |

    Bhardwaj et al. report that adding Flt3 ligand to the treatment strategy effectively increased DC populations and increased T-cell responses in a randomized phase II trial of a DC-targeted vaccine for the melanoma antigen NY-ESO-1.

    • Nina Bhardwaj
    • , Philip A. Friedlander
    • , Anna C. Pavlick
    • , Marc S. Ernstoff
    • , Brian R. Gastman
    • , Brent A. Hanks
    • , Brendan D. Curti
    • , Mark R. Albertini
    • , Jason J. Luke
    • , Ana B. Blazquez
    • , Sreekumar Balan
    • , Davide Bedognetti
    • , Joseph M. Beechem
    • , Andrea S. Crocker
    • , Leonard D’Amico
    • , Patrick Danaher
    • , Thomas A. Davis
    • , Thomas Hawthorne
    • , Bruce W. Hess
    • , Tibor Keler
    • , Lisa Lundgren
    • , Chihiro Morishima
    • , Nirasha Ramchurren
    • , Darawan Rinchai
    • , Andres M. Salazar
    • , Bob A. Salim
    • , Elad Sharon
    • , Laura A. Vitale
    • , Ena Wang
    • , Sarah Warren
    • , Michael J. Yellin
    • , Mary L. Disis
    • , Martin A. Cheever
    •  & Steven P. Fling
  • Article |

    Samstein et al. report that mutations in BRCA1 and BRCA2 result in distinct mutational genomic landscapes, effects on the tumor-immune microenvironment and response to immune checkpoint therapy.

    • Robert M. Samstein
    • , Chirag Krishna
    • , Xiaoxiao Ma
    • , Xin Pei
    • , Ken-Wing Lee
    • , Vladimir Makarov
    • , Fengshen Kuo
    • , Jonathan Chung
    • , Raghvendra M. Srivastava
    • , Tanaya A. Purohit
    • , Douglas R. Hoen
    • , Rajarsi Mandal
    • , Jeremy Setton
    • , Wei Wu
    • , Rachna Shah
    • , Besnik Qeriqi
    • , Qing Chang
    • , Sviatoslav Kendall
    • , Lior Braunstein
    • , Britta Weigelt
    • , Pedro Blecua Carrillo Albornoz
    • , Luc G. T. Morris
    • , Diana L. Mandelker
    • , Jorge S. Reis-Filho
    • , Elisa de Stanchina
    • , Simon N. Powell
    • , Timothy A. Chan
    •  & Nadeem Riaz
  • Article |

    Goel and colleagues show that CDK4/6 inhibition induces global chromatin changes mediated by AP-1 factors, which mediate key biological and clinical effects in breast cancer.

    • April C. Watt
    • , Paloma Cejas
    • , Molly J. DeCristo
    • , Otto Metzger-Filho
    • , Enid Y. N. Lam
    • , Xintao Qiu
    • , Haley BrinJones
    • , Nikolas Kesten
    • , Rhiannon Coulson
    • , Alba Font-Tello
    • , Klothilda Lim
    • , Raga Vadhi
    • , Veerle W. Daniels
    • , Joan Montero
    • , Len Taing
    • , Clifford A. Meyer
    • , Omer Gilan
    • , Charles C. Bell
    • , Keegan D. Korthauer
    • , Claudia Giambartolomei
    • , Bogdan Pasaniuc
    • , Ji-Heui Seo
    • , Matthew L. Freedman
    • , Cynthia Ma
    • , Matthew J. Ellis
    • , Ian Krop
    • , Eric Winer
    • , Anthony Letai
    • , Myles Brown
    • , Mark A. Dawson
    • , Henry W. Long
    • , Jean J. Zhao
    •  & Shom Goel
  • Article |

    Quezada and colleagues develop improved anti-CD25 antibodies that preserve IL-2 signaling and enhance single-agent antitumor immunity and immunotherapy through specific and efficient Treg cell depletion.

    • Isabelle Solomon
    • , Maria Amann
    • , Anne Goubier
    • , Frederick Arce Vargas
    • , Dimitrios Zervas
    • , Chen Qing
    • , Jake Y. Henry
    • , Ehsan Ghorani
    • , Ayse U. Akarca
    • , Teresa Marafioti
    • , Anna Śledzińska
    • , Mariana Werner Sunderland
    • , Dafne Franz Demane
    • , Joanne Ruth Clancy
    • , Andrew Georgiou
    • , Josephine Salimu
    • , Pascal Merchiers
    • , Mark Adrian Brown
    • , Reto Flury
    • , Jan Eckmann
    • , Claudio Murgia
    • , Johannes Sam
    • , Bjoern Jacobsen
    • , Estelle Marrer-Berger
    • , Christophe Boetsch
    • , Sara Belli
    • , Lea Leibrock
    • , Joerg Benz
    • , Hans Koll
    • , Roger Sutmuller
    • , Karl S. Peggs
    •  & Sergio A. Quezada

News & Comment

  • Editorial |

    Nature Cancer encourages preprint sharing as a valuable means of research dissemination and scholarly communication.

  • News & Views |

    Invariant natural killer T cells (iNKT cells) are innate-like CD1d-restricted T cells that have NK cell–like properties and bear an invariant T cell receptor (iTCR). iNKT cells have shown potential for cancer immunotherapy. A study now shows that stabilization of the iTCR–CD1d complex via a single-chain bi-specific antibody stimulates iNKT cell–mediated anti-tumor immunity.

    • Mark A. Exley
    • , Thomas Gensollen
    •  & Richard S. Blumberg
  • Comment |

    Recent advances in cancer neuroscience necessitate the systematic analysis of neural influences in cancer as potential therapeutic targets in oncology. Here we outline recommendations for future preclinical and translational research in this field.

    • Ihsan Ekin Demir
    • , Carmen Mota Reyes
    • , Wasfi Alrawashdeh
    • , Güralp O. Ceyhan
    • , Sylvie Deborde
    • , Helmut Friess
    • , Kıvanç Görgülü
    • , Rouzanna Istvanffy
    • , David Jungwirth
    • , Rohini Kuner
    • , Maria Maryanovich
    • , Shorook Na’ara
    • , Simon Renders
    • , Jami L. Saloman
    • , Nicole N. Scheff
    • , Hendrik Steenfadt
    • , Pavel Stupakov
    • , Vera Thiel
    • , Divij Verma
    • , Bengi Su Yilmaz
    • , Ruth A. White
    • , Timothy C. Wang
    • , Richard J. Wong
    • , Paul S. Frenette
    • , Ziv Gil
    •  & Brian M. Davis
  • Cancer in Translation |

    Although RET alterations are relatively frequent across tumor types, specific targeting of RET in the clinic has been challenging. Ambrogio, Aggarwal and colleagues provide their views on how mechanistic studies have swiftly translated into powerful targeted therapies in two recent clinical studies that led to the FDA approval of selpercatinib for certain tumors in which RET is altered.

    • Melina E. Marmarelis
    • , Roberto Chiarle
    • , Chiara Ambrogio
    •  & Charu Aggarwal
  • News & Views |

    Tumor-specific changes in DNA methylation are both acquired actively through transcription-coupled processes and passively accumulated over time. Analysis across B cell malignancies now shows that these changes provide insight into the cellular origin as well as the proliferative history of tumors and thereby have diagnostic value and prognostic value, respectively.

    • Paolo Strati
    •  & Michael R. Green
  • News & Views |

    Mitochondrial DNA damage, metabolic disruption and aging have all been associated with cancer. These three threads are now woven together to show that aging-associated somatic mutations to mitochondrial DNA alter mitochondrial serine metabolism to support cell transformation and colon-cancer development.

    • Hiran A. Prag
    •  & Michael P. Murphy